We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
TRUQAP (AstraZeneca Pty Ltd)
Product name
TRUQAP
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
207 (255 working days)
Active ingredients
capivasertib
Registration type
NCE/NBE
Indication
TRUQAP is indicated in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative (defined as IHC 0 or 1+, or IHC 2+/ISH-) locally advanced or metastatic breast cancer following recurrence or progression on or after an endocrine based regimen.